Marshall Wace LLP Sells 23,381 Shares of Amedisys, Inc. (NASDAQ:AMED)

Marshall Wace LLP lessened its position in Amedisys, Inc. (NASDAQ:AMED) by 8.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 268,122 shares of the health services provider’s stock after selling 23,381 shares during the period. Marshall Wace LLP owned about 0.82% of Amedisys worth $24,614,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AMED. Banque Cantonale Vaudoise bought a new position in Amedisys in the 1st quarter valued at approximately $60,000. Innealta Capital LLC bought a new position in shares of Amedisys during the second quarter valued at $64,000. Covestor Ltd boosted its position in shares of Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after buying an additional 447 shares during the last quarter. Signaturefd LLC increased its holdings in Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares in the last quarter. Finally, GAM Holding AG bought a new stake in Amedisys in the 2nd quarter worth about $275,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Stock Performance

Shares of NASDAQ AMED opened at $97.16 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys, Inc. has a 12-month low of $89.55 and a 12-month high of $98.95. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -151.81, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The firm has a 50 day moving average of $97.63 and a 200 day moving average of $94.93.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping the consensus estimate of $1.22 by $0.10. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. The firm had revenue of $591.19 million during the quarter, compared to analyst estimates of $579.34 million. On average, research analysts anticipate that Amedisys, Inc. will post 4.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AMED shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a report on Thursday, July 25th. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft cut Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target on the stock. in a report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amedisys has a consensus rating of “Hold” and an average target price of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.